Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 1.460
Filter
2.
An. pediatr. (2003. Ed. impr.) ; 92(4): 241.e1-241.e11, abr. 2020. mapas, graf, tab
Article in Spanish | IBECS | ID: ibc-186847

ABSTRACT

El 31 de diciembre de 2019, la Comisión Municipal de Salud y Sanidad de Wuhan (provincia de Hubei, China) informó sobre la existencia de 27 casos de neumonía de etiología desconocida con inicio de síntomas el 8 de diciembre, incluyendo 7 casos graves, con exposición común a un mercado de marisco, pescado y animales vivos en la ciudad de Wuhan. El 7 de enero de 2020, las autoridades chinas identificaron como agente causante del brote un nuevo tipo de virus de la familia Coronaviridae, denominado temporalmente «nuevo coronavirus», 2019-nCoV. El 30 de enero de 2020 la Organización Mundial de la Salud (OMS) declara el brote una Emergencia Internacional. El día 11 de febrero la OMS le asigna el nombre de SARS-CoV2 e infección COVID-19 (Coronavirus Infectious Disease). El Ministerio de Sanidad convoca a las Sociedades de Especialidades para la elaboración de un protocolo clínico de manejo de la infección. La Asociación Española de Pediatría nombra un grupo de trabajo de las Sociedades de Infectología Pediátrica y Cuidados Intensivos Pediátricos que se encargan de elaborar las presentes recomendaciones con la evidencia disponible en el momento de su realización


On 31 December 2019, the Wuhan Municipal Committee of Health and Healthcare (Hubei Province, China) reported that there were 27 cases of pneumonia of unknown origin with symptoms starting on the 8 December. There were 7 serious cases with common exposure in market with shellfish, fish, and live animals, in the city of Wuhan. On 7 January 2020, the Chinese authorities identified that the agent causing the outbreak was a new type of virus of the Coronaviridae family, temporarily called «new coronavirus», 2019-nCoV. On January 30th, 2020, the World Health Organisation (WHO) declared the outbreak an International Emergency. On 11 February 2020 the WHO assigned it the name of SARS-CoV2 and COVID-19 (SARS-CoV2 and COVID-19). The Ministry of Health summoned the Specialties Societies to prepare a clinical protocol for the management of COVID-19. The Spanish Paediatric Association appointed a Working Group of the Societies of Paediatric Infectious Diseases and Paediatric Intensive Care to prepare the present recommendations with the evidence available at the time of preparing them


Subject(s)
Humans , Infant , Child, Preschool , Child , Adolescent , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Coronavirus/classification , Coronavirus/genetics , Real-Time Polymerase Chain Reaction , Severity of Illness Index , Societies, Medical , Spain
3.
Aten. prim. (Barc., Ed. impr.) ; 52(6): 0-0, jun.-jul. 2020.
Article in English | IBECS | ID: ibc-187536

ABSTRACT

The novel coronavirus SARS-CoV-2 is a positive single-stranded RNA virus that can be immediately translated and integrated into the host cell with its own RNA messenger, facilitating replication inside the cell and infectivity. The rapid progression of the disease presents a real challenge for the whole world. As the usual capacity for citizen care is exceeded, health professionals and governments struggle. One of the most important strategies to reduce and mitigate the advance of the epidemic are social distance measures; this is where telemedicine can help, and provide support to the healthcare systems, especially in the areas of public health, prevention and clinical practices, just as it is doing in others sectors. Telemedicine connects the convenience, low cost, and ready accessibility of health-related information and communication using the Internet and associated technologies. Telemedicine during the coronavirus epidemic has been the doctors’ first line of defense to slow the spread of the coronavirus, keeping social distancing and providing services by phone or videoconferencing for mild to focus personal care and limited supplies to the most urgent cases


El nuevo coronavirus SARS-CoV-2 es un virus de ARN monocatenario positivo que puede traducirse inmediatamente e integrarse en la célula huésped con su propio mensajero de ARN, facilitando la replicación dentro de la célula y la infectividad. La rápida progresión de la enfermedad presenta un verdadero desafío en todas las partes del mundo. A medida que se excede la capacidad habitual de atención sanitaria a los ciudadanos pueden generarse tensiones entre los profesionales de la salud y los gobiernos. Una de las estrategias más importantes para reducir y mitigar el avance de la epidemia son las medidas de distanciamiento social. Aquí es donde la telemedicina puede ayudar y brindar apoyo a los sistemas de salud, especialmente en las áreas de salud, prevención y prácticas clínicas, tal como se está están haciendo en otros sectores. La telemedicina conecta la conveniencia, el bajo costo y la fácil accesibilidad de la información y la comunicación relacionadas con la salud a través de Internet y las tecnologías asociadas. La telemedicina durante la epidemia de coronavirus ha sido la primera línea de defensa de los sanitarios para para frenar la propagación del coronavirus, brindando servicios por teléfono o videoconferencia para atención personalizada en casos leves y limitando los recursos sanitarios para los casos más urgentes


Subject(s)
Humans , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Betacoronavirus , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Pandemics , Telemedicine/methods , Telemonitoring
4.
Rev Infirm ; 69(260-261): 31-32, 2020.
Article in French | MEDLINE | ID: mdl-32600593

ABSTRACT

Originating in China in November 2019, the wave of infection caused by the new coronavirus Sars-CoV-2 is sweeping across the planet through human contact and fast, global, mass travel. Health professionals on every level are fighting relentlessly against Covid-19, this deadly, invisible yet real enemy. The public, increasingly worried, expect them to protect it against the disease and death. Perceived by most people as a line of defence against the pandemic, health professionals are supported and treated as heroes. Some people howeverfear tthat they may be possible contamination agents.


Subject(s)
Attitude to Health , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Health Personnel , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , China/epidemiology , Coronavirus Infections/transmission , Courage , Humans , Infectious Disease Transmission, Professional-to-Patient , Pneumonia, Viral/transmission
5.
Article in English | MEDLINE | ID: mdl-32602672

ABSTRACT

It aimed to evaluate the perception of safety and preparedness among health workers caring for coronavirus disease 2019 (COVID-19) patients before and after a multi-professional simulation-based course in Pakistan. Health workers' perception of preparedness, safety, and their willingness to care for COVID-19 patients were measured before after attending a simulation-based training course to prepare them to care for COVID-19 patients, in Combined Military Hospital Landi Kotal Cantt, from 1st March 2020 to 30th April 2020. : The participants' perceived level of safety and preparedness to care for COVID-19 patients before the simulation-based course was low but increased after completing it (P<0.05). They felt confident and were willing to a significantly higher degree to care for patients of COVID-19 or other infections requiring high isolationSimulation-based training is an effective tool to improve the perception of risk and readiness to deal with COVID-19 among medical and non-medical health workers in Pakistan.


Subject(s)
Coronavirus Infections/therapy , Interprofessional Relations , Personnel, Hospital/education , Personnel, Hospital/psychology , Pneumonia, Viral/therapy , Simulation Training/methods , Adult , Coronavirus Infections/epidemiology , Female , Humans , Male , Middle Aged , Pakistan/epidemiology , Pandemics , Personnel, Hospital/statistics & numerical data , Pneumonia, Viral/epidemiology , Program Evaluation , Safety , Self Efficacy , Young Adult
6.
BMJ Case Rep ; 13(6)2020 Jun 30.
Article in English | MEDLINE | ID: mdl-32606105

ABSTRACT

A 4-month-old boy with a history of muscular ventricular septal defect and atopic dermatitis presented with decreased oral intake, loose stools, stuffy nose, mild cough and diaphoresis. The patient had an in-home exposure to COVID-19. The initial respiratory pathogen panel was positive for adenovirus, consistent with his symptoms. The following day, the COVID-19 PCR was also positive. The patient was treated with supportive care, isolation precautions were implemented and the patient was discharged on day 4. This case demonstrates the importance of testing for COVID-19 even if a patient tests positive for another virus due to the possibility of coinfection, especially in children, in order to limit spread of COVID-19 to others.


Subject(s)
Adenoviridae Infections/diagnosis , Coinfection/virology , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , Adenoviridae Infections/therapy , Betacoronavirus , Coronavirus Infections/therapy , Humans , Infant , Male , Pandemics , Pneumonia, Viral/therapy
7.
Sr Care Pharm ; 35(7): 286-291, 2020 Jul 01.
Article in English | MEDLINE | ID: mdl-32600505

ABSTRACT

Pharmacists across various practice settings are joining the fight against COVID-19, empowered by the resources available through national, governmental and professional organizations. Long-term care pharmacists are instrumental in optimizing medication management and developing policies to reduce the risk of COVID-19 transmission among vulnerable residents.


Subject(s)
Coronavirus Infections/prevention & control , Coronavirus Infections/therapy , Pandemics/prevention & control , Pharmacists , Pneumonia, Viral/prevention & control , Pneumonia, Viral/therapy , Professional Role , Betacoronavirus , Humans
8.
Sr Care Pharm ; 35(7): 331, 2020 Jul 01.
Article in English | MEDLINE | ID: mdl-32600512

ABSTRACT

The Centers for Medicare & Medicaid Services (CMS) and other federal agencies are busy churning out regulations and guidance documents in response to the COVID-19 crisis. CMS now requires plans to waive cost sharing for COVID-19-related immunizations, testing, and treatment and suspend utilization review requirements related to drug-supply limits unless these limits are related to patient safety.


Subject(s)
Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Medicaid/organization & administration , Medicare/organization & administration , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Betacoronavirus , Coronavirus Infections/economics , Coronavirus Infections/prevention & control , Drug Utilization , Humans , Pandemics/economics , Pandemics/prevention & control , Pneumonia, Viral/economics , Pneumonia, Viral/prevention & control , United States
9.
Internet resource in Portuguese | LIS -Health Information Locator, LIS-bvsms | ID: lis-LISBR1.1-47638

ABSTRACT

Noticia publicada no site do Ministério da Saúde (Brasil) , em 22 de jun. de 2020 pela Agencia de Saúde , informa que mais de 760 municípios já podem implantar Centros de Atendimento para enfrentamento da Covid-19. Portaria libera R$ 251,4 milhões em recursos temporários para reforçar a identificação precoce de casos da doença...


Subject(s)
Coronavirus Infections/therapy , Betacoronavirus , Ambulatory Care Facilities , Cities
11.
Rev. Hosp. Ital. B. Aires (2004) ; 40(2): 53-55, jun. 2020. ilus
Article in Spanish | LILACS | ID: biblio-1102484

ABSTRACT

Una de las características de la afección pulmonar por enfermedad por coronavirus (COVID-19) es la disociación entre la gravedad de la hipoxemia y el mantenimiento de una mecánica respiratoria relativamente conservada. En este contexto se ha establecido una teoría en relación con dos fenotipos de pacientes con síndrome de distrés respiratorio del adulto (SDRA): un fenotipo Low, caracterizado por baja elastancia y baja reclutabilidad, y un fenotipo High, con características de alta elastancia y alta reclutabilidad. Presentamos el caso de un paciente que cursó internación en la Unidad de Terapia Intensiva de Adultos de nuestro hospital, con clínica, mecánica ventilatoria y patrón tomográfico compatible con el fenotipo Low de SDRA por COVID-19. (AU)


Dissociation between severity of hypoxemia and relative preserved respiratory mechanics is a characteristic observed in lung impairment due to coronavirus disease (COVID-19). Patients with COVID-19 that present adult respiratory distress syndrome (ARDS) are identified for one of two phenotypes according to a theory recently established. The Low phenotype is distinguished by low elastance and low recruitability; and the High phenotype, by high elastance and high recruitability. The case describes a patient admitted in the adult Intensive Care Unit of Hospital Italiano de Buenos Aires with observed symptoms, ventilatory mechanics and tomographic pattern that are compatible with Low phenotype of ARDS due to COVID-19. (AU)


Subject(s)
Humans , Male , Middle Aged , Respiratory Distress Syndrome, Adult/microbiology , Coronavirus Infections/therapy , Phenotype , Respiratory Distress Syndrome, Adult/genetics , Respiratory Mechanics , Coronavirus Infections/diagnosis , Coronavirus Infections/physiopathology , Cough/etiology , Dyspnea/etiology , Fever/etiology , Hypertension/complications , Intensive Care Units , Hypoxia/physiopathology , Obesity/complications
12.
Rev. Hosp. Ital. B. Aires (2004) ; 40(2): 63-75, jun. 2020. graf, ilus, tab
Article in Spanish | LILACS | ID: biblio-1102739

ABSTRACT

El objetivo de este artículo es proporcionar una guía que sirva para la interpretación y seguimiento de los esfuerzos que se están desarrollando en todo el mundo con el objetivo de obtener una vacuna que pueda generar inmunidad contra el nuevo coronavirus SARS-CoV-2 de 2019, el agente causante de la enfermedad por coronavirus denominada COVID-19. Cinco meses después de haber sido detectada la enfermedad, ya hay 102 vacunas en distintos estadios de desarrollo, registradas por la Organización Mundial de la Salud (OMS), correspondientes a 8 plataformas vacunales con diferentes estrategias, y todos los días aparecen nuevas. Esto representará un enorme desafío de organismos internacionales, para la evaluación, comparación y selección de aquellas que cumplan con los criterios regulatorios indispensables de seguridad y eficacia y que, por otro lado, puedan ser producidas en cantidades suficientes para abastecer la demanda mundial. (AU)


The objective of this article is to provide a guide to help the interpretation and monitoring the efforts that are being carried out worldwide to obtain a vaccine that will be able to generate immunity against the new 2019 SARS-CoV-2 coronavirus, the viral agent causes the disease named COVID-19. Five months after the disease was detected, there are already 102 vaccines at different stages of development, registered by World Health Organization (WHO), corresponding to 8 vaccination platforms base on different strategies, and every day new ones appear. This will represent a huge challenge for international organizations, to evaluate, compare and selects those that will meet the essential regulatory criteria of safety and efficacy and that, would be able to be produced in enough quantities to supply the worldwide demand. Key words: SARS-Cov-2 vaccine, vaccine platform, COVID-19 strategy, attenuated virus, viral vector, viral proteins, viral DNA, viral RNA, nucleic acids, viral like particles, WHO. (AU)


Subject(s)
Humans , Male , Female , Coronavirus Infections/therapy , SARS Virus/immunology , Pneumonia, Viral/therapy , DNA/therapeutic use , RNA/therapeutic use , Vaccines/therapeutic use , Nucleic Acids/therapeutic use , Protein S/immunology , Coronavirus Infections/virology , SARS Virus/physiology , SARS Virus/genetics , Disease Vectors
13.
Dtsch Med Wochenschr ; 145(11): 740-746, 2020 Jun.
Article in German | MEDLINE | ID: mdl-32492743

ABSTRACT

- Case numbers in China are clearly declining, case numbers in many European regions are no longer increasing exponentially.- Data on mortality from SARS-CoV-2 infection are contradictory; mortality is certainly lower than for SARS and MERS, but probably higher than for most seasonal flu outbreaks in recent years- The main complication of SARS-CoV-2 infection is pneumonia with development of acute respiratory distress syndrome (ARDS)- Asymptomatic and oligosymptomatic courses with virus shedding are not uncommon; they may be more frequent in children than in adults. Virus excretion in asymptomatic people and in the pre-symptomatic phase of an infection is relevant for transmission- An effective antiviral therapy has not yet been established. Steroids for anti-inflammatory therapy are not recommended- It is very important to prepare all actors in the health care system for a longer-term burden of inpatients and complications and to create the necessary capacities. Low-threshold diagnostic testing and rapid detection of infection chains remain essential for better control of the pandemic. An effective vaccine is urgent.


Subject(s)
Coronavirus Infections/epidemiology , Pandemics/classification , Pneumonia, Viral/classification , Coronavirus Infections/classification , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Coronavirus Infections/virology , Global Health/statistics & numerical data , Humans
14.
Monaldi Arch Chest Dis ; 90(2)2020 May 14.
Article in English | MEDLINE | ID: mdl-32498503

ABSTRACT

The enduring epidemic outbreak which started in Wuhan city of China, in December 2019 caused by the 2019 novel coronavirus (COVID- 19) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has created a dangerous and deadly Public Health disaster of International apprehension, with cases confirmed in several countries. This novel community health trouble is frightening the universe with clinical, psychological, emotional, collapse of health system and economical slowdown in each and every part of the world infecting nearly 200 countries. A highly virulent and pathogenic COVID-19 viral infection with incubation period ranging from two to fourteen days, transmitted by breathing of infected droplets or contact with infected droplets, belongs to the genus Coronavirus with its high mutation rate in the Coronaviridae. The likely probable primary reservoir could be bats, because genomic analysis discovered that SARSCoV-2 is phylogenetically interrelated to SARS-like bat viruses. The transitional resource of origin and transfer to humans is not known, however, the rapidly developing pandemic has confirmed human to human transfer. Approximately 1,016,128 reported cases, 211,615 recovered cases and 53,069 deaths of COVID-2019 have been reported to date (April 2, 2020). The symptoms vary from asymptomatic, low grade pyrexia, dry cough, sore throat, breathlessness, tiredness, body aches, fatigue, myalgia, nausea, vomiting, diarrhea, to severe consolidation and pneumonia, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction leading to death with case fatality rate ranging from 2 to 3%.


Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/epidemiology , Disease Outbreaks , Pneumonia, Viral/epidemiology , Animals , Antiviral Agents/administration & dosage , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Drug Development , Global Health , Humans , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Public Health , Real-Time Polymerase Chain Reaction/methods , Reverse Transcriptase Polymerase Chain Reaction/methods
16.
Theranostics ; 10(13): 5932-5942, 2020.
Article in English | MEDLINE | ID: mdl-32483428

ABSTRACT

On the 30th of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe. In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells. In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19.


Subject(s)
Betacoronavirus , Coronavirus Infections/therapy , Nanoparticles/therapeutic use , Pneumonia, Viral/therapy , Theranostic Nanomedicine/methods , Administration, Intranasal , Antiviral Agents/administration & dosage , Betacoronavirus/drug effects , Betacoronavirus/genetics , Betacoronavirus/immunology , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Drug Delivery Systems/methods , Humans , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/genetics , Vaccines, Virus-Like Particle/administration & dosage , Viral Vaccines/administration & dosage , Viral Vaccines/immunology , Virus Internalization/drug effects
17.
J Investig Med High Impact Case Rep ; 8: 2324709620933438, 2020.
Article in English | MEDLINE | ID: mdl-32500773

ABSTRACT

In this article, we present a case of a young female patient with previously diagnosed lupus pneumonitis, now with a flare and new superimposed COVID-19 infection that was treated with intravenous steroids. On computed tomography scans, she had extensive interstitial lung fibrosis in addition to a positive COVID-19 polymerase chain reaction test requiring 6 L of oxygen via nasal cannula on admission. After administration of methylprednisolone, the patient improved and was weaned off her oxygen requirements and was discharged home.


Subject(s)
Coronavirus Infections/complications , Lupus Erythematosus, Systemic/complications , Pneumonia, Viral/complications , Pneumonia/complications , Antibodies, Antinuclear/immunology , Antirheumatic Agents/therapeutic use , Betacoronavirus , Cardiac Tamponade , Complement C3/immunology , Complement C4/immunology , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/drug therapy , Coronavirus Infections/therapy , DNA , Disease Progression , Enzyme Inhibitors/therapeutic use , Female , Fibrin Fibrinogen Degradation Products , Glucocorticoids/therapeutic use , Humans , Hydroxychloroquine/therapeutic use , Lung/diagnostic imaging , Lupus Erythematosus, Systemic/diagnostic imaging , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/immunology , Lupus Nephritis , Lymphopenia/etiology , Methylprednisolone/therapeutic use , Mycophenolic Acid/therapeutic use , Oxygen Inhalation Therapy , Pandemics , Pneumonia/diagnostic imaging , Pneumonia/immunology , Pneumonia/therapy , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/therapy , Tomography, X-Ray Computed , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL